Мнение по проблеме. Спиронолактон: новый поворот старой истории

В материале представлены последние данные о возможностях более широкого применения антагонистов минералокортикоидных рецепторов по имеющимся показаниям, а также расширении показаний к применению этой группы препаратов в контексте новой коронавирусной инфекции 2019 года. Обсуждаются перспективы более широкого выявления альдостеронизма с помощью нового диагностического подхода, включающего дополнительную оценку реакции артериального давления на спиронолактон.

1. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Circulation. 2000;102(22):2700–6. PMID: 11094035

2. Скворцов А.А., Нарусов О.Ю., Муксинова М.Д., Протасов В.Н., Протасова Д.Е., Кузнецова Т.В. и др. Клиническое значение серийного определения активности современных биомаркеров у больных после декомпенсации сердечной недостаточности: роль sST2 и NT-proBNP при длительном наблюдении. Кардиология. 2018;58(12S):27-41. DOI: 10.18087/cardio.2634

3. Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H et al. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. New England Journal of Medicine. 2011;364(1):11–21. DOI: 10.1056/NEJMoa1009492

4. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018;39(33):3021–104. DOI: 10.1093/eurheartj/ehy339

5. Кобалава Ж.Д., Конради А.О., Недогода С.В., Шляхто Е.В., Арутюнов Г.П., Баранова Е.И. и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):149-218. DOI: 10.15829/1560-4071-2020-3-3786

6. Carey RM, Douglas JG, Schweikert JR, Liddle GW. The syndrome of essential hypertension and suppressed plasma renin activity. Normalization of blood pressure with spironolactone. Archives of Internal Medicine. 1972;130(6):849–54. PMID: 5082464

7. Rodilla E, Costa JA, Pérez-Lahiguera F, Baldó E, González C, Pascual JM. Spironolactone and Doxazosin Treatment in Patients With Resistant Hypertension. Revista Española de Cardiología (English Edition). 2009;62(2):158–66. DOI: 10.1016/S1885-5857(09)71534-8

8. Lane DA, Shah S, Beevers DG. Low-dose spironolactone in the management of resistant hypertension: a surveillance study. Journal of Hypertension. 2007;25(4):891–4. DOI: 10.1097/HJH.0b013e328014954d

9. Gaddam K, Pimenta E, Thomas SJ, Cofield SS, Oparil S, Harding SM et al. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. Journal of Human Hypertension. 2010;24(8):532–7. DOI: 10.1038/jhh.2009.96

10. Engbaek M, Hjerrild M, Hallas J, Jacobsen IA. The effect of lowdose spironolactone on resistant hypertension. Journal ofthe American Society of Hypertension. 2010;4(6):290–4. DOI: 10.1016/j.jash.2010.10.001

11. Chapman N, Dobson J, Wilson S, Dahlöf B, Sever PS, Wedel H et al. Effect of Spironolactone on Blood Pressure in Subjects With Resistant Hypertension. Hypertension. 2007;49(4):839–45. DOI: 10.1161/01.HYP.0000259805.18468.8c

12. Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT et al. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. The Lancet Diabetes & Endocrinology. 2018;6(6):464–75. DOI: 10.1016/S2213-8587(18)30071-8

13. Conn JW. Primary aldosteronism. The Journal of Laboratory and Clinical Medicine. 1955;45(4):661–4. PMID: 14368032

14. Funder J. Primary aldosteronism. Trends in Cardiovascular Medicine. 2021;S1050-1738(21)00043-8. [Epub ahead of print]. DOI: 10.1016/j.tcm.2021.03.005

15. Xu F, Gao Z, Wang G, Gao Y, Guo Y, Guo Y et al. Prevalence, Subtype Classification, and Outcomes of Treatment of Primary Aldosteronism: A Prospective Study in China. Endocrine Practice. 2021;27(5):478–83. DOI: 10.1016/j.eprac.2020.10.007

16. Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH et al. The Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study. Annals of Internal Medicine. 2020;173(1):10–20. DOI: 10.7326/M20-0065

17. Pilz S, Grübler MR, Theiler-Schwetz V, Malle O, Trummer C. The Unrecognized Prevalence of Primary Aldosteronism. Annals of Internal Medicine. 2020;173(8):681–2. DOI: 10.7326/L20-1094

18. Vaidya A, Carey RM. Evolution of the Primary Aldosteronism Syndrome: Updating the Approach. The Journal of Clinical Endocrinology & Metabolism. 2020;105(12):3771–83. DOI: 10.1210/clinem/dgaa606

19. Ruilope LM, Ruiz-Hurtado G, Tamargo J. Adequate blood pressure control unattainable without adequate recognition and treatment of primary aldosteronism. Trends in Cardiovascular Medicine. 2021;S1050-1738(21)00047-5. [Epub ahead of print]. DOI: 10.1016/j.tcm.2021.04.003

20. Mehdi A, Rao P, Thomas G. Our evolving understanding of primary aldosteronism. Cleveland Clinic Journal of Medicine. 2021;88(4):221–7. DOI: 10.3949/ccjm.88a.20166

21. Kaneko H, Umakoshi H, Ogata M, Wada N, Iwahashi N, Fukumoto T et al. Machine learning based models for prediction of subtype diagnosis of primary aldosteronism using blood test. Scientific Reports. 2021;11(1):9140. DOI: 10.1038/s41598-021-88712-8

22. Li N, Huang J, Zheng B, Cai H, Liu M, Liu L. Cost‐effectiveness Analysis of Screening for Primary Aldosteronism in China. Clinical Endocrinology. 2021;95(3):414–22. DOI: 10.1111/cen.14478

23. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-280.e8. DOI: 10.1016/j.cell.2020.02.052

24. Mackey K, King VJ, Gurley S, Kiefer M, Liederbauer E, Vela K et al. Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults: A Living Systematic Review. Annals of Internal Medicine. 2020;173(3):195–203. DOI: 10.7326/M20-1515

25. Chen Z-W, Tsai C-H, Pan C-T, Chou C-H, Liao C-W, Hung C-S et al. Endothelial Dysfunction in Primary Aldosteronism. International Journal of Molecular Sciences. 2019;20(20):5214. DOI: 10.3390/ijms20205214

26. Vicenzi M, Di Cosola R, Ruscica M, Ratti A, Rota I, Rota F et al. The liaison between respiratory failure and high blood pressure: evidence from COVID-19 patients. European Respiratory Journal. 2020;56(1):2001157. DOI: 10.1183/13993003.01157-2020

27. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. New England Journal of Medicine. 2020;383(2):120–8. DOI: 10.1056/NEJMoa2015432

28. Wang J, Wang BJ, Yang JC, Wang MY, Chen C, Luo GX et al. Research advances in the mechanism of pulmonary fibrosis induced by coronavirus disease 2019 and the corresponding therapeutic measures. Zhonghua Shao Shang Za Zhi. 2020;36(8):691–7. DOI: 10.3760/cma.j.cn501120-20200307-00132

29. Zhao H, Gu DW, Li HT, Ge QF, Li GP. Inhibitory effects of spironolactone on myocardial fibrosis in spontaneously hypertensive rats. Genetics and Molecular Research. 2015;14(3):10315–21. DOI: 10.4238/2015.August.28.17

30. Funder JW. Spironolactone in cardiovascular disease: an expanding universe? F1000Research. 2017;6:1738. DOI: 10.12688/f1000research.11887.1

31. Yavas G, Yavas C, Celik E, Sen E, Ata O, Afsar RE. The impact of spironolactone on the lung injury induced by concomitant trastuzumab and thoracic radiotherapy. International Journal of Radiation Research. 2019;17(1):87–95. DOI: 10.18869/acadpub.ijrr.17.1.87

32. Ji W-J, Ma Y-Q, Zhou X, Zhang Y-D, Lu R-Y, Guo Z-Z et al. Spironolactone Attenuates Bleomycin-Induced Pulmonary Injury Partially via Modulating Mononuclear Phagocyte Phenotype Switching in Circulating and Alveolar Compartments. PLoS ONE. 2013;8(11):e81090. DOI: 10.1371/journal.pone.0081090

33. Barut F, Ozacmak VH, Turan I, Sayan-Ozacmak H, Aktunc E. Reduction of Acute Lung Injury by Administration of Spironolactone After Intestinal Ischemia and Reperfusion in Rats. Clinical & Investigative Medicine. 2016;39(1):E15-24. DOI: 10.25011/cim.v39i1.26326

34. Asselta R, Paraboschi EM, Mantovani A, Duga S. ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy. 2020. [Av. at: http://medrxiv.org/lookup/doi/10.1101/2020.03.30.20047878].

35. Atalay C, Dogan N, Aykan S, Gundogdu C, Keles MS. The efficacy of spironolactone in the treatment of acute respiratory distress syndrome-induced rats. Singapore Medical Journal. 2010;51(6):501–5. PMID: 20658111

36. Chen D, Li X, Song Q, Hu C, Su F, Dai J et al. Assessment of Hypokalemia and Clinical Characteristics in Patients with Coronavirus Disease 2019 in Wenzhou, China. JAMA Network Open. 2020;3(6):e2011122. DOI: 10.1001/jamanetworkopen.2020.11122

37. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A et al. Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study. New England Journal of Medicine. 2004;351(6):543–51. DOI: 10.1056/NEJMoa040135

38. Villard O, Morquin D, Molinari N, Raingeard I, Nagot N, Cristol J-P et al. The Plasmatic Aldosterone and C-Reactive Protein Levels, and the Severity of Covid-19: The Dyhor-19 Study. Journal of Clinical Medicine. 2020;9(7):2315. DOI: 10.3390/jcm9072315

39. Jeon D, Son M, Choi J. Effect of Spironolactone on COVID-19 in Patients With Underlying Liver Cirrhosis: A Nationwide Case-Control Study in South Korea. Frontiers in Medicine. 2021;8:629176. DOI: 10.3389/fmed.2021.629176

40. Мареев В.Ю., Орлова Я.А., Плисюк А.Г., Павликова Е.П., Мацкеплишвили С.Т., Акопян Ж.А. и др. Результаты открытого проспективного контролируемого сравнительного исследования по лечению новой коронавирусной инфекции (COVID-19): Бромгексин И Спиронолактон для лечения КоронаВирусной Инфекции, Требующей госпитализации (БИСКВИТ). Кардиология. 2020;60(11):4-15. DOI: 10.18087/cardio.2020.11.1440

41. Мареев В.Ю., Орлова Я.А., Павликова Е.П., Мацкеплишвили С.Т., Акопян Ж.А., Плисюк А.Г. и др. Возможности комбинированной терапии на раннем этапе течения новой коронавирусной инфекции (COVID-19). Разбор клинических случаев и дизайн исследования: Бромгексин И Спиронолактон для лечения КоронаВирусной Инфекции, Требующей госпитализации (БИСКВИТ). Кардиология. 2020;60(8):4–15. DOI: 10.18087/cardio.2020.8.n1307

42. Vicenzi M, Ruscica M, Iodice S, Rota I, Ratti A, Di Cosola R et al. The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients. Journal of Clinical Medicine. 2020;9(9):2943. DOI: 10.3390/jcm9092943